Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,174.61
-1.49 (-0.13%)
At close: Aug 28, 2026
Eli Lilly Revenue
Eli Lilly had revenue of $22.97B in the quarter ending June 30, 2026, with 47.67% growth. This brings the company's revenue in the last twelve months to $79.67B, up 49.58% year-over-year. In the year 2025, Eli Lilly had annual revenue of $65.18B with 44.70% growth.
Revenue (ttm)
$79.67B
Revenue Growth
+49.58%
P/S Ratio
13.14
Revenue / Employee
$1,593,320
Employees
50,000
Market Cap
1.05T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.18B | 20.14B | 44.70% |
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | 1.52B | 7.61% |
| Dec 31, 2017 | 19.97B | -1.25B | -5.88% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
LLY News
- 40 minutes ago - Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. - Barrons
- 48 minutes ago - Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA - TheFly
- 50 minutes ago - Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion - WSJ
- 1 hour ago - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity - PRNewsWire
- 1 hour ago - Eli Lilly to buy Merida Biosciences in $2.88 billion deal - Reuters
- 1 hour ago - Eli Lilly to acquire Merida Biosciences for $2.88B in cash - TheFly
- 1 hour ago - Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - PRNewsWire
- 3 days ago - US FDA approves Lilly's Mounjaro to reduce cardiovascular risk - Reuters